Buscar
Talphera Inc
TLPHAñadir a la lista de seguimiento
0.848USD
-0.050-5.52%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
44.01MCap. mercado
PérdidaP/E TTM
Más Datos de Talphera Inc Compañía
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Información de Talphera Inc
Símbolo de cotizaciónTLPH
Nombre de la empresaTalphera Inc
Fecha de salida a bolsaFeb 11, 2011
Director ejecutivoAngotti (Vincent J)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 11
Dirección1850 Gateway Drive
CiudadSAN MATEO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94404
Teléfono16502163500
Sitio Webhttps://talphera.com/
Símbolo de cotizaciónTLPH
Fecha de salida a bolsaFeb 11, 2011
Director ejecutivoAngotti (Vincent J)
Ejecutivos de Talphera Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
25.39K
-205.17%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
-31.98%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
6.40K
--
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
-92.92%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
2.75K
-144.41%
Dr. Stephen J. Hoffman, M.D., Ph.D.
Dr. Stephen J. Hoffman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Vincent J. (Vince) Angotti
Mr. Vincent J. (Vince) Angotti
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Raffi M. Asadorian
Mr. Raffi M. Asadorian
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Marina S. Bozilenko
Ms. Marina S. Bozilenko
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Badri N. Dasu
Mr. Badri N. Dasu
Chief Engineering Officer
Chief Engineering Officer
45.03K
-5.43%
Dr. Shakil Aslam
Dr. Shakil Aslam
Chief Development Officer, Chief Medical Officer
Chief Development Officer, Chief Medical Officer
25.39K
-205.17%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
13.34K
-31.98%
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Director
Director
6.40K
--
Mr. Mark Allen Wan
Mr. Mark Allen Wan
Independent Director
Independent Director
4.59K
-92.92%
Mr. Abhinav (Abi) Jain
Mr. Abhinav (Abi) Jain
Independent Director
Independent Director
2.75K
-144.41%
Desglose de ingresos
Divisa: USDActualizado: 5 de mar de 2025
Divisa: USDActualizado: 5 de mar de 2025
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Otro
0.00
0.00%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
DSUVIA
1.59M
89.67%
DZUVEO
183.00K
10.33%
Zalviso
0.00
0.00%
Non-cash royalty revenue related to Royalty Monetization
0.00
0.00%
Other revenue
0.00
0.00%
Otro
0.00
0.00%
Estadísticas de accionistas
Actualizado: jue., 14 de may
Actualizado: jue., 14 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
CorMedix Inc
17.52%
Rock Springs Capital Management LP
6.92%
Rosalind Advisors, Inc.
6.90%
AIGH Capital Management, LLC.
6.55%
Lytton (Laurence W)
5.26%
Otro
56.86%
Accionistas
Accionistas
Proporción
CorMedix Inc
17.52%
Rock Springs Capital Management LP
6.92%
Rosalind Advisors, Inc.
6.90%
AIGH Capital Management, LLC.
6.55%
Lytton (Laurence W)
5.26%
Otro
56.86%
Tipos de accionistas
Accionistas
Proporción
Corporation
17.52%
Hedge Fund
15.02%
Individual Investor
6.73%
Private Equity
6.55%
Investment Advisor
4.89%
Investment Advisor/Hedge Fund
4.38%
Research Firm
0.44%
Otro
44.47%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
68
20.36M
40.00%
+746.54K
2025Q4
65
18.51M
39.72%
+8.77M
2025Q3
65
12.68M
31.11%
+4.13M
2025Q2
79
6.96M
33.93%
-506.98K
2025Q1
82
6.66M
34.60%
-832.94K
2024Q4
84
5.24M
30.79%
-2.31M
2024Q3
100
5.33M
31.39%
-2.35M
2024Q2
109
5.51M
32.40%
-2.29M
2024Q1
113
5.56M
32.76%
-881.00K
2023Q4
117
5.91M
35.12%
-445.19K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
CorMedix Inc
9.09M
18.16%
+9.09M
--
Sep 10, 2025
Rock Springs Capital Management LP
3.59M
7.17%
--
--
Dec 31, 2025
Rosalind Advisors, Inc.
3.58M
7.15%
-806.48K
-18.39%
Dec 31, 2025
AIGH Capital Management, LLC.
3.40M
6.79%
+382.48K
+12.69%
Dec 31, 2025
Lytton (Laurence W)
2.73M
5.46%
-905.65K
-24.91%
Dec 31, 2025
Worth Venture Partners, LLC
1.26M
2.53%
-175.52K
-12.19%
Dec 31, 2025
Bleichroeder LP
881.17K
1.76%
--
--
Dec 31, 2025
Angotti Vincent J
674.09K
1.35%
+213.31K
+46.29%
Mar 13, 2026
Empery Asset Management, L.P.
1.33M
2.66%
+1.33M
--
Dec 31, 2025
Cantor Fitzgerald, L.P
577.49K
1.15%
+577.49K
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
Oct 25, 2022
Merger
20→1
